NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 02/06/24
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 02/02/24
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual MeetingGlobeNewsWire • 10/19/23
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development StrategyGlobeNewsWire • 08/31/23
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/10/23
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual MeetingGlobeNewsWire • 06/05/23
NexImmune Reports First Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/15/23
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual MeetingGlobeNewsWire • 04/26/23
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/28/23
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRGlobeNewsWire • 02/16/23